JP2012518425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518425A5 JP2012518425A5 JP2011551521A JP2011551521A JP2012518425A5 JP 2012518425 A5 JP2012518425 A5 JP 2012518425A5 JP 2011551521 A JP2011551521 A JP 2011551521A JP 2011551521 A JP2011551521 A JP 2011551521A JP 2012518425 A5 JP2012518425 A5 JP 2012518425A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody
- antibody molecule
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 238000000034 method Methods 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 6
- 210000004698 lymphocyte Anatomy 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0903325.9 | 2009-02-26 | ||
| GBGB0903325.9A GB0903325D0 (en) | 2009-02-26 | 2009-02-26 | Antibody molecules |
| PCT/GB2010/000351 WO2010097597A1 (en) | 2009-02-26 | 2010-02-26 | Antibodies specifically directed to the soluble form of ctla-4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518425A JP2012518425A (ja) | 2012-08-16 |
| JP2012518425A5 true JP2012518425A5 (enExample) | 2013-04-18 |
| JP5864266B2 JP5864266B2 (ja) | 2016-02-17 |
Family
ID=40565800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551521A Expired - Fee Related JP5864266B2 (ja) | 2009-02-26 | 2010-02-26 | 可溶型のｃｔｌａ−４に特異的に対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8697845B2 (enExample) |
| EP (1) | EP2401035B1 (enExample) |
| JP (1) | JP5864266B2 (enExample) |
| CN (1) | CN102421482B (enExample) |
| AU (1) | AU2010217453B2 (enExample) |
| CA (1) | CA2772648A1 (enExample) |
| ES (1) | ES2662652T3 (enExample) |
| GB (1) | GB0903325D0 (enExample) |
| WO (1) | WO2010097597A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| EP2983661B1 (en) | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| NZ739503A (en) | 2015-07-16 | 2023-06-30 | Bioxcel Therapeutics Inc | A novel approach for treatment of cancer using immunomodulation |
| CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| SG11201804969PA (en) * | 2015-12-15 | 2018-07-30 | Oncoimmune Inc | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
| EP3400023A1 (en) | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| MA45037A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polythérapie à base d'arnm pour le traitement du cancer |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| IL266918B2 (en) | 2016-12-07 | 2024-03-01 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
| WO2018107004A1 (en) | 2016-12-08 | 2018-06-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
| US20190382490A1 (en) * | 2017-02-28 | 2019-12-19 | Bristol-Myers Squibb Company | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
| WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| IL275391B2 (en) * | 2017-12-20 | 2025-05-01 | Harbour Biomed Shanghai Co Ltd | Antibodies binding ctla-4 and uses thereof |
| JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
| JP7369127B2 (ja) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体 |
| KR102839330B1 (ko) | 2018-01-15 | 2025-07-30 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| CN114174336B (zh) | 2019-07-15 | 2024-10-11 | 英特维特国际股份有限公司 | 针对人和犬ctla-4的犬源化抗体 |
| US12435143B2 (en) | 2019-07-15 | 2025-10-07 | Intervet Inc. | Caninized antibodies against canine CTLA-4 |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CA3186777A1 (en) * | 2020-06-11 | 2021-12-16 | Nantbio, Inc. | Anti-ctla4 monoclonal antibodies and chimeric antigen receptors |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US6107056A (en) * | 1996-02-22 | 2000-08-22 | Oaks; Martin K. | SCTLA-4 gene and product |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7109003B2 (en) * | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| AU2001255398A1 (en) * | 2000-04-12 | 2001-10-30 | Genetics Institute Inc. | Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor |
| AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
| US7939634B2 (en) | 2004-01-27 | 2011-05-10 | Compugen Ltd. | Polynucleotides encoding polypeptides and methods using same |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| GB0426644D0 (en) * | 2004-12-03 | 2005-01-05 | Univ Aberdeen | T-cell modulation |
| WO2007067959A2 (en) * | 2005-12-07 | 2007-06-14 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
| US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| US8598321B2 (en) * | 2007-03-22 | 2013-12-03 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| WO2008156621A1 (en) * | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2009
- 2009-02-26 GB GBGB0903325.9A patent/GB0903325D0/en not_active Ceased
-
2010
- 2010-02-26 AU AU2010217453A patent/AU2010217453B2/en not_active Ceased
- 2010-02-26 JP JP2011551521A patent/JP5864266B2/ja not_active Expired - Fee Related
- 2010-02-26 ES ES10706034.5T patent/ES2662652T3/es active Active
- 2010-02-26 WO PCT/GB2010/000351 patent/WO2010097597A1/en not_active Ceased
- 2010-02-26 US US13/203,418 patent/US8697845B2/en active Active
- 2010-02-26 CA CA2772648A patent/CA2772648A1/en not_active Abandoned
- 2010-02-26 EP EP10706034.5A patent/EP2401035B1/en not_active Not-in-force
- 2010-02-26 CN CN201080018428.9A patent/CN102421482B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518425A5 (enExample) | ||
| JP7317272B2 (ja) | Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。 | |
| JP7046804B2 (ja) | 改良された血清アルブミン結合剤 | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| US9145454B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| JP2014528695A5 (enExample) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP7646768B2 (ja) | 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途 | |
| CN112574308A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP7711208B2 (ja) | Ｄｌｌ３に対する結合分子及びその使用 | |
| CN112513088A (zh) | 抗ox40抗体、其抗原结合片段及其医药用途 | |
| CN118339187A (zh) | 抗pd-1抗体及其用途 | |
| CN113651884A (zh) | 人源化抗SARS-CoV-2单克隆抗体及其应用 | |
| CN116547300B (zh) | 双特异性抗体及其应用 | |
| JP2022534624A (ja) | 活性化抗ｇａｌ９結合分子 | |
| US20250312438A1 (en) | Humanized constructs, vaccines, and methods | |
| WO2024188341A1 (zh) | 特异性结合Claudin18.2的抗体及其制法和应用 | |
| EP3946452A1 (en) | Anti-hla-c antibodies and uses thereof | |
| TWI906795B (zh) | 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用 | |
| CN115386003B (zh) | 抗SARS-CoV-2鼠源单克隆抗体及其应用 | |
| KR102845060B1 (ko) | 니파바이러스 및 헨드라바이러스에 특이적인 단클론항체 및 이의 용도 | |
| TWI789679B (zh) | 抗人程序性死亡配體-1（pd-l1）的抗體及其用途 | |
| CN114907474B (zh) | 抗冠状病毒抗体、其筛选方法、含有该抗体的药物组合物及应用 |